LUCIUS 卢修斯 航可来昔替尼 Deucravacitinib斑块型银屑病

航可来昔替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Deucravacitinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Compositien:

LUCIUS

斑块型银屑病

Caco him-cozled tablel contain
Densravacitinih
LuciDeucra is a tyrosine kinase 2(79K2) inhibitor

PHARMACEUTICALS

indicated for the trestment of adults with moderate-
lo-severe plaque psoriasis who are candidtes for
systemic therapy or phototheroy.

LuciDeucra

rmended for use in combination with oth
Desage and Use:
*For recommended evaluation prior to LuciDeuc
nitiztion,see Full Prescribine Information

Deucravacitinib Tablets

FDA批准

ded dosage is e ig orally once daly,

with or without food
Storage: in a dry place and store at 20°C to 25°C
Warning:

6mg

Kcep medicine out of texch of Childrer Do
ser LuciDeacra durine Preonenev and
Lactation

PLEASESEE PACKAGE INSERT
Manufactared and Marketed by:

Rx Only

LUCIUS

权威认证

Ca44)uany district, Vientiane

Warning: Te be sold by retail on prescrioti

by the phsicen

30 Tablets

口碑质量

适应症:
用于治疗适合全身治疗或光疗的中度至重度斑块
型银屑病成人患者。
推荐剂量:
每日口服一次,每次6mg,随餐或不随餐均可。